01.- 02.07.2021 | European Organ-on-Chip Society (EUROoCS) 2021
Conference Venue: Virtual Event
Go to the Conference website here
Dr. Bettina Lickiss (innoVitro GmbH) will present the following poster:
A physiological environment for human iPSC-derived cardiomyocytes facilitates maturation for reliable preclinical cardiac risk evaluation on high throughput level
Abstract:
In pre-clinical drug development, cardiac contraction analysis of potential drug candidates is one of the crucial steps to ensure a successful and reliable transition to clinical stages. The use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) continues to increase in the assessment of safety and toxicological side effects of newly developed compounds, due to their reproducibility and low ethical concern.In pre-clinical drug development, cardiac contraction analysis of potential drug candidates is one of the crucial steps to ensure a successful and reliable transition to clinical stages. The use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) continues to increase in the assessment of safety and toxicological side effects of newly developed compounds, due to their reproducibility and low ethical concern.However, their premature phenotype causes issues concerning non-physiological responses to positive inotropic compounds. Acute testing within limited timescales (min to h) after compound application remains the primary application of hiPSC-CMs so far, partly due to the inability of common cell-based assays to analyze cellular behavior reliably over prolonged periods of time.
Interested to learn more about the European Organ-on-Chip Society
Click here to learn more.